Vapotherm (VAPO)
(Delayed Data from OTC)
$1.26 USD
0.00 (0.00%)
Updated Apr 19, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VAPO 1.26 0.00(0.00%)
Will VAPO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VAPO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VAPO
Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates
Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates
VAPO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
Analysts Estimate PetIQ (PETQ) to Report a Decline in Earnings: What to Look Out for
Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline
Other News for VAPO
Vapotherm Secures New $4 Million Senior Secured Loan
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market